How does volume affect BoomRx pricing?

Ask BoomRx specific, written questions about volume. At what monthly or quarterly order volume does your per-vial rate change? Does the improvement apply across all SKUs or only high-volume GLP-1s? If you miss a volume commitment, does the rate reset? And does volume affect only drug cost, or also platform fees? Aggregated network buying can genuinely lower cost at scale, but without published tiers you are negotiating blind until those answers are in writing.

Also model shipping separately. A $30 flat fee per patient order is predictable, but it does not shrink as your drug volume grows — so at high volume your per-vial shipping drag may improve only if you batch more vials per patient order, not because the fee itself drops. Compare delivered per-vial cost at your current volume and at your projected volume, not just the headline drug rate.

Fizy Health does not ask you to guess volume tiers. It shows resolved per-vial 503A cost on each catalog and cart line before checkout, with a disclosed facilitation fee at payment, so you can model margin at today's volume immediately and re-check as you scale. That does not replace network negotiation — it replaces opacity. You see the number on every SKU before you order, then decide whether BoomRx portal pricing at your projected volume beats it.

Run the comparison on your real SKUs. Get written BoomRx per-vial cost at your current and projected volume, add the $30 shipping fee per patient order, and set that against visible pass-through cost plus facilitation fee on the same drug, strength, and vial size. Whichever delivers lower delivered per-vial cost at the volume you actually run is the right economics — but only a side-by-side test proves it.